AMPK Phosphorylates ZDHHC13 to Increase MC1R Activity and Suppress Melanomagenesis.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
04 04 2023
Historique:
received: 16 08 2022
revised: 22 12 2022
accepted: 24 01 2023
medline: 5 4 2023
pubmed: 27 1 2023
entrez: 26 1 2023
Statut: ppublish

Résumé

Inherited genetic variations in the melanocortin-1 receptor (MC1R) responsible for human red hair color (RHC) variants are associated with impaired DNA damage repair and increased melanoma risk. MC1R signaling is critically dependent on palmitoylation, primarily mediated by the protein acyltransferase zinc finger DHHC-type palmitoyltransferase 13 (ZDHHC13). A better understanding of how ZDHHC13 is physiologically activated could help identify approaches to prevent melanomagenesis in redheads. Here, we report that AMP-activated protein kinase (AMPK) phosphorylates ZDHHC13 at S208 to strengthen the interaction between ZDHHC13 and MC1R-RHC, leading to enhanced MC1R palmitoylation in redheads. Consequently, phosphorylation of ZDHHC13 by AMPK increased MC1R-RHC downstream signaling. AMPK activation and MC1R palmitoylation repressed UVB-induced transformation of human melanocytes in vitro and delayed melanomagenesis in vivo in C57BL/6J-MC1R-RHC mice. The importance of AMPK to MC1R signaling was validated in human melanomas where AMPK upregulation correlated with expression of factors downstream from MC1R signaling and with prolonged patient survival. These findings suggest AMPK activation as a promising strategy to reduce melanoma risk, especially for individuals with red hair. Phosphorylation of ZDHHC13 by AMPK at S208 promotes MC1R activation and suppresses melanocyte transformation, indicating activation of AMPK as a potential approach to prevent melanoma in people with red hair.

Identifiants

pubmed: 36701140
pii: 716224
doi: 10.1158/0008-5472.CAN-22-2595
pmc: PMC10073341
mid: NIHMS1870920
doi:

Substances chimiques

AMP-Activated Protein Kinases EC 2.7.11.31
ZDHHC13 protein, human EC 2.3.1.-
MC1R protein, human 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1062-1073

Subventions

Organisme : NCI NIH HHS
ID : R00 CA234097
Pays : United States
Organisme : NCI NIH HHS
ID : K99 CA234097
Pays : United States

Informations de copyright

©2023 American Association for Cancer Research.

Références

Nature. 2006 Sep 21;443(7109):340-4
pubmed: 16988713
Cancer Res. 2010 May 1;70(9):3547-56
pubmed: 20388774
Front Cell Dev Biol. 2021 Feb 15;9:626404
pubmed: 33659252
Sci Signal. 2016 Nov 08;9(453):ra109
pubmed: 27919027
Sci Signal. 2017 Jan 31;10(464):
pubmed: 28143904
Sci Rep. 2017 May 19;7(1):2182
pubmed: 28526873
J Hepatol. 2018 Sep;69(3):705-717
pubmed: 29705240
Pharmacol Ther. 2003 Jan;97(1):1-33
pubmed: 12493533
Mol Cell. 2013 Aug 22;51(4):409-22
pubmed: 23973372
Mol Cell Biol. 2010 Feb;30(3):806-19
pubmed: 19933846
Nat Genet. 2009 May;41(5):544-52
pubmed: 19282848
Mol Biol Cell. 2012 Jan;23(1):188-99
pubmed: 22031296
Mol Cell. 2013 Oct 24;52(2):161-72
pubmed: 24095280
Nat Commun. 2018 Jan 17;9(1):259
pubmed: 29343685
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Physiology (Bethesda). 2011 Aug;26(4):214-24
pubmed: 21841070
J Invest Dermatol. 1986 Apr;86(4):433-7
pubmed: 3528310
Biochem Biophys Res Commun. 2015 May 8;460(3):709-14
pubmed: 25824042
Oncogene. 2006 Oct 12;25(47):6262-76
pubmed: 16702958
Mol Cancer Ther. 2009 Apr;8(4):733-41
pubmed: 19372545
Nat Cell Biol. 2011 Feb;13(2):132-41
pubmed: 21258367
Nat Commun. 2019 Feb 20;10(1):877
pubmed: 30787281
Sci Rep. 2017 Oct 16;7(1):12796
pubmed: 29038583
Nat Biotechnol. 2020 Jun;38(6):675-678
pubmed: 32444850
FEBS Lett. 1987 Nov 2;223(2):217-22
pubmed: 2889619
Nature. 2012 Nov 15;491(7424):449-53
pubmed: 23123854
Biochem Biophys Res Commun. 1999 Jul 5;260(2):488-91
pubmed: 10403794
Eur J Pharmacol. 2011 Oct 15;668(3):373-82
pubmed: 21806981
J Biol Chem. 2011 Nov 11;286(45):39247-58
pubmed: 21917926
Cell Metab. 2015 Nov 3;22(5):907-21
pubmed: 26456332
Nat Rev Mol Cell Biol. 2012 Mar 22;13(4):251-62
pubmed: 22436748
Pigment Cell Res. 2005 Dec;18(6):393-410
pubmed: 16280005
J Biol Chem. 2017 Feb 17;292(7):2979-2991
pubmed: 28057756
Cell Death Dis. 2011 Sep 01;2:e199
pubmed: 21881601
Nat Cell Biol. 2011 Sep 02;13(9):1016-23
pubmed: 21892142
JAMA Dermatol. 2016 Jul 1;152(7):776-82
pubmed: 27050141
Int J Cancer. 2006 Oct 15;119(8):1976-84
pubmed: 16721784
J Invest Dermatol. 2022 Feb;142(2):293-302.e1
pubmed: 34362555
Nat Biomed Eng. 2019 Apr;3(4):306-317
pubmed: 30952982
MMWR Morb Mortal Wkly Rep. 2015 Jun 5;64(21):591-6
pubmed: 26042651
Nature. 2017 Sep 21;549(7672):399-403
pubmed: 28869973
Nature. 2005 Jul 7;436(7047):117-22
pubmed: 16001072
Mol Cell Biol. 2006 Jul;26(14):5336-47
pubmed: 16809770
Nat Commun. 2019 Jan 10;10(1):104
pubmed: 30631047
Semin Cancer Biol. 2022 Oct;85:52-68
pubmed: 33862221
Oncogene. 2018 Sep;37(36):4941-4954
pubmed: 29786078
Br J Cancer. 2015 Jul 14;113(2):354-63
pubmed: 26103569
Nat Struct Biol. 1999 Feb;6(2):157-65
pubmed: 10048928
Peptides. 2005 Oct;26(10):1965-71
pubmed: 15963603
Cell Death Dis. 2021 Oct 12;12(10):934
pubmed: 34642298

Auteurs

Yu Sun (Y)

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.

Xin Li (X)

Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts.

Chengqian Yin (C)

Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts.

Judy Zhang (J)

Cleveland Clinic Lerner College of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio.

Ershang Liang (E)

The Graduate School of Arts and Sciences, Fordham University, Bronx, New York.

Xianfang Wu (X)

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Infection Biology Program, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.

Ying Ni (Y)

Center for Immunotherapy & Precision Immuno-Oncology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.

Joshua Arbesman (J)

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.

Colin R Goding (CR)

Ludwig Institute for Cancer Research, University of Oxford, Headington, Oxford, United Kingdom.

Shuyang Chen (S)

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH